Skip to main content

Grafa News and Videos — Page 1642

Latest

Grafa

Corcept Therapeutics announces FDA approval of Lifyorli™ for platinum-resistant ovarian cancer

Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company pioneering the modulation of cortisol to treat severe disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved Lifyorli™ (relacorilant).

Read more: Corcept Therapeutics announces FDA approval of Lifyorli™ for platinum-resistant ovarian cancer
Grafa

Denali Therapeutics achieves landmark FDA approval for first brain-penetrant Hunter Syndrome therapy

Denali Therapeutics (NASDAQ:DNLI), a biopharmaceutical company dedicated to developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB), announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for AVLAYAH™ (tividenofusp alfa-eknm).

Read more: Denali Therapeutics achieves landmark FDA approval for first brain-penetrant Hunter Syndrome therapy
Grafa

Maze Therapeutics reports success in Phase 2 kidney disease trial as cash runway extends into 2028

Maze Therapeutics (NASDAQ:MAZE), a clinical-stage biopharmaceutical company applying genetic insights to the development of precision medicines, reported its fourth-quarter and full-year 2025 financial results on Wednesday, March 25, 2026.

Read more: Maze Therapeutics reports success in Phase 2 kidney disease trial as cash runway extends into 2028

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift